hIL23A/hIL12B

Nomenclature

C57BL/6Smoc-Il23atm3(hIL23A)Il12btm3(hIL12B)Smoc

Cat. NO.

NM-HU-233778

Strain State

Repository Live

Export PDF

Model Description

The hIL12B(NM-HU-2000057) was crossed with hIL23A(NM-HU-18030) to generate hIL23A/hIL12B mice.

Validation Data

image.png

Fig.1 Detection of hIL23 and mIL23 expression in serum by ELISA (n=2). 

Abbr. HO, homozygous; WT, wild type.

Note. hIL23A/hIL12B and C57BL/6 mice were i.p. injected with LPS.

image.png

Table.1 Blood chemistry examination in 6-week-old HO/HO hIL23A/hIL12B mice (n=3 /group).

image.png

image.png

Table.2 Blood routine examination in 6-week-old HO/HO hIL23A/hIL12B mice (n=3 /group).

image.png

Fig.2 In vivo efficacy evaluation of anti-IL23 (Risankizumab, 20mpk, i.p., Q3D) and anti-IL23/IL12 (Ustekinumab, 20mpk, i.p., Q3D) in imiquimod (IMQ)-induced psoriasis model in hIL23A/hIL12B mice (3-6 mice/group, 6 weeks, female). IMQ treatment induced body weight loss in female hIL23A/hIL12B mice. Neither Risankizumab nor Ustekinumab treatment alleviated this weight loss, with both antibody-treated groups showing final body weight reductions.

image.png

Fig.3 In vivo efficacy evaluation of anti-IL23 (Risankizumab, 20mpk, i.p., Q3D) and anti-IL23/IL12 (Ustekinumab, 20mpk, i.p., Q3D) in imiquimod (IMQ)-induced psoriasis model in hIL23A/hIL12B mice (3-6 mice/group, 6 weeks, female). IMQ treatment successfully induced psoriasis-like skin inflammation in female hIL23A/hIL12B mice, characterized by increased skin thickness and elevated PASI scores (including erythema and scaling) over the 7-day observation period. Notably, Risankizumab demonstrated better therapeutic effect than Ustekinumab in lleviating IMQ-induced psoriasis.



You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more